TORONTO, ONTARIO--(Marketwired - April 22, 2014) - Prism Medical Ltd., ("Prism Medical" or "the Company") (TSX VENTURE:PM), a leading provider of durable medical equipment and related services to the mobility challenged, today reported financial results for the first quarter (Q1) ended February 28, 2014.
||Three months ended February 28
||As a % of revenues
||As a % of revenues
||As a % of revenues
|Earnings per share
Expressed in thousands of Canadian dollars except for earnings per share and where otherwise noted.
First Quarter Highlights
- The acquisition of the remaining 51% interest in MedCare in Minneapolis, USA in February 2014
- Growth in North American revenues as the company expands its install base in new geographic markets
United Kingdom (UK)
UK revenues for the three months ended February 28, 2014 increased $1,311 or 15% compared to the same period last year. The improvement in the British pound by over 13% over the prior year's quarter positively impacted revenues in the current quarter. Revenues remained stable on a year over year basis despite the continued impact of fiscal restraints in the UK, the healthcare market remains solid.
United States (US)
US revenues for the three months ended February 28, 2014 increased $1,235 or 24% compared to the same period last year due to incremental sales in our hospital group business, homecare and sales to institutional dealers. US revenues were positively impacted by the improvement in the US dollar over the prior year's quarter representing over a 9% appreciation.
Canada revenues for the three months ended February 28, 2014 increased $484 or 16% compared to the same period last year. New provincial program spending in Saskatchewan has led the increase. Continued market share improvements are being achieved in Ontario offset by declines in provincial spending in British Columbia. New distributed product sales also contributed to the increase.
Gross margin for the three months ended February 28, 2014 increased $1,324 or 19.5% compared to the same period last year due to higher revenues across all businesses. Gross margin rates remained constant at 40.7%.
Selling, General and Administrative
Selling, general and administrative expenses for the three months ended February 28, 2014 were $6,940 compared to $6,306 for the same period last year, an increase of $634 or 10.1%. The Company has strengthened its human capital particularly in the US positioning itself for growth in the North American market. UK selling, general and administrative expenses remained constant excluding the impact of the improvement in the British pound.
The first quarter adjusted EBITDA performance was $2,064 compared to $1,314, an increase of $750 or 57% over the prior year.
Net Income for the quarter increased by $609 or to $668 compared to $59 for the comparable period last year and earnings per share for the same periods increased from $0.01 per share to $0.08 per share. The North American market has demonstrated strong growth for the quarter compared to the prior year.
As at February 28, 2014, the Company had cash of $1,149 and bank indebtedness of $9,759 compared to cash of $2,069 and bank indebtedness of $8,789 respectively, as at November 30, 2013.
EVENTS AFTER THE REPORTING PERIOD
On April 11, 2014, the Company announced the share sale of its UK subsidiary for cash consideration of GBP 30 million or CAD $54.9 million. The sale occurred pursuant to a Sale and Purchase Agreement ("Purchase Agreement") entered into and completed on April 11,2014 with a new company backed by LDC (Managers) Limited, a UK mid-market private equity firm that is a subsidiary of Lloyds Banking Group. Pursuant to the Purchase Agreement, the Purchaser acquired all of the shares of the Company's UK holding company, Prism UK Medical Limited ("Prism UK"). The CAD $54.9 million gross proceeds is expected to result in CAD $49.5 million in net cash proceeds after deducting transaction expenses, related taxes and head office restructuring costs. The Purchase Agreement contains customary representations and warranty obligations with a further GBP 314,000 (CAD $575,000) to be placed in escrow for two years as security for the Company's indemnity and warranty obligations. The Company is also entitled to certain additional "earn out" payments to a maximum of GBP 500,000 and additional consideration based on future sales by Prism UK in North America, Central and South America and Japan for the 3 years following the close of the transaction. The Company has also agreed not to compete with Prism UK in the UK, Europe and the Middle East for a period of 3 years from closing of the transaction.
In conjunction with the transaction, the Company has renegotiated its senior credit facilities. The key terms such as covenants, interest rates and margin ratios have remained unchanged. However, the overall credit limits decreased due to the lower asset base going forward. The Company's operating line has decreased from $17.5 million to $10 million and its acquisition line has decreased from $27.5 million to $10 million.
The Company will use its reasonable commercial efforts to complete a share buy back through a substantial issuer bid ("SIB") within the next four months to return to shareholders CAD $35 million to CAD $40 million of the net cash proceeds of the sale. The completion of the SIB will be subject to customary conditions and the satisfaction of all necessary legal and regulatory requirements. The Company intends to retain the remainder of the proceeds to reduce debt levels to be well within approved bank credit limits and to fund growth opportunities.
On April 22, 2014, the Board of Directors approved a dividend payment of $0.08 per common share to shareholders of record on May 14, 2014 payable on May 22, 2014.
The Company intends to grow sales and profitability and provide a reasonable return on shareholders' equity with a focus on the North American market. The Company believes that performance will be positively affected by a continued North American institutional and homecare demand for our products, improved manufacturing efficiencies, greater geographic coverage, and revenues and profits from new product introductions. During the past year the Company's North American operations have materially improved. Management believes that there are significant growth opportunities within the expanding North American health care industry both through organic growth and acquisitions that offer the potential to significantly increase shareholder value, while remaining consistent with Prism Medical's key growth strategies of vertical integration, product diversification and the application of relevant knowledge by its service oriented personnel.
About Prism Medical Ltd.
Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverly Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. The Company offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. In addition, the Company through its network of Nightingale dealers provides an integrated suite of products and services that make home care a viable option for many people. For further information visit Prism Medical's website at www.prismmedicalltd.com or www.sedar.com.
1Non-IFRS Financial Measures
Prism Medical's consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS). The Company also uses non‐IFRS measures such as Adjusted EBITDA to measure its financial performance. Adjusted EBITDA consists of earnings before interest, income taxes, depreciation, amortization, stock‐based compensation. Adjusted EBITDA is a financial metric used by many investors to compare companies on the basis of operating results, asset value and the ability to incur and service debt. Management believes that Adjusted EBITDA is a useful measure for evaluating the performance of the Company. Adjusted EBITDA is not a recognized measure under IFRS and does not have a standardized meaning prescribed by IFRS and may not be comparable to similarly titled financial metrics reported by other companies.
This document contains forward-looking statements relating to our operations and to the environment in which we operate and our strategy, action plans and investments, which may involve estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and/or are beyond our control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in this report and our other public filings. Consequently, readers should not place any undue reliance on such forward-looking statements. These forward-looking statements are made as of the date of this report. Prism Medical is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. All forward-looking statements attributable to Prism Medical are expressly qualified by these cautionary statements.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.